Netherlands Government Pushes for Flavor Ban on E-Cigarettes

Sep.15.2022
Netherlands Government Pushes for Flavor Ban on E-Cigarettes
The Netherlands government considers banning flavored e-cigarettes due to concerns about their appeal to young people.

Recently, the Dutch government has reopened the debate surrounding the ban of flavored e-cigarettes in response to public consultation. This is a long-standing issue, dating back to June 2020, when the Deputy Minister of Health, Paul Blokhuis, expressed concerns about delays and opposing views to the proposed ban during a consultation process.


However, nothing is hindering the determination of the administrative department as they move forward. In fact, current public consultations are not limited to a simple ban on non-tobacco flavors in e-cigarette liquids, but are constrained by a list developed by the National Institute for Public Health and the Environment (Rivm), which approves production of only sixteen ingredients. This will effectively ban current e-cigarette liquids on the market, including tobacco flavor liquids, making development of new liquids extremely difficult according to experts. The European Tobacco Harm Reduction Advocates (Ethra) commented, "In fact, this is a hidden ban on all e-cigarette liquids. This will be the end of the legal e-cigarette market in the Netherlands and will create a very dangerous precedent for other EU countries.


The Netherlands government's intention with the flavor ban on e-cigarettes is to reduce their appeal to the population as a whole, especially young people. However, as seen in other places, this ban could potentially deprive adult smokers in the Netherlands of a valuable tool to quit smoking, thereby increasing smoking rates. Additionally, this ban may also lead to illegal and unregulated sales channels.


Statement:


This article is compiled from third-party information and is intended for industry professionals for the purpose of exchanging and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The article's translation is intended only for industry exchange and research.


Due to limitations in translation skills, the translated article may not fully express the same meaning as the original. Therefore, readers should refer to the original article for accuracy.


2FIRSTS aligns completely with the Chinese government's stance and statements on any domestic, Hong Kong, Macau, Taiwan, or foreign issues.


The copyright of the compiled information belongs to the original media and the author. If there is any infringement, please kindly contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Australia's tobacco tax revenue has halved in five years, with the illegal cigarette market exceeding $4 billion
Australia's tobacco tax revenue has halved in five years, with the illegal cigarette market exceeding $4 billion
Australia's tobacco tax revenue is falling to its lowest point in a decade, projected to be just $4.9 billion in the 2025-26 fiscal year, nearly half the amount collected in 2019-20. This decline is primarily due to the prevalence of illicit cigarettes, which exceeded $4 billion in the black market in 2022-23 and generated an estimated $6.6 billion in revenue for criminal organizations. Medical professionals warn that cheap, contraband cigarettes on the streets are driving a resurgence in smokin
Sep.24 by 2FIRSTS.ai
UK Advocacy Groups Launch "20IsPlenty" Campaign for Nicotine Pouch Strength Limit of 20mg
UK Advocacy Groups Launch "20IsPlenty" Campaign for Nicotine Pouch Strength Limit of 20mg
UK harm reduction groups led by We Vape have launched the “20IsPlenty” campaign calling for a 20mg nicotine pouch cap, a ban on youth advertising, and evidence-based regulation. The initiative coincides with the Tobacco and Vapes Bill debate and aims to ensure pouches remain accessible as safer alternatives for smokers.
Oct.28 by 2FIRSTS.ai
Company|BAT Invests in Expansion of Italian Factory, Adding 16 Production Lines for Heated Tobacco and Nicotine Pouches
Company|BAT Invests in Expansion of Italian Factory, Adding 16 Production Lines for Heated Tobacco and Nicotine Pouches
BAT Italy will expand its Trieste plant, adding 16 new production lines for heated tobacco cartridges, nicotine pouches, and nicotine replacement therapy products. The expansion adds 6,300 m² of space, bringing the total to 30,000 m². This is part of BAT’s €500 million five-year investment plan launched in 2023.
Sep.15 by 2FIRSTS.ai
NSW Government Plans Harsh Penalties for Landlords Allowing Illegal Tobacco and E-Cigarette Sales
NSW Government Plans Harsh Penalties for Landlords Allowing Illegal Tobacco and E-Cigarette Sales
New South Wales to crack down on landlords tolerating illegal tobacco and e-cigarette sales by tenants, with severe penalties.
Nov.12 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
InterTabac 2025 Insights|PMI Showcases Full Portfolio: IQOS, VEEV, and ZYN in Dedicated Zones
InterTabac 2025 Insights|PMI Showcases Full Portfolio: IQOS, VEEV, and ZYN in Dedicated Zones
At InterTabac 2025 in Dortmund, 2Firsts observed that Philip Morris International (PMI) exhibited with a full product lineup and organized three key brands—IQOS (heated tobacco), VEEV (e-vapor), and ZYN (nicotine pouches)—into separate display areas.
Sep.19 by 2FIRSTS.ai